CARLAT WEBINAR Ketamine and the Evolving Psychopharmacologic Pipeline for Depression December 8, 2023 Robert C. Meisner, MD 0.50 CME Credits. Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians. Read More
General PsychiatryKarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change EverythingRead More
Psychology and Social WorkTreating BPD Series, Episode 2: Transference-Focused Psychotherapy—From Splitting to Coherence with Frank Yeomans, MD, PhD In this episode, Dr. Frank Yeomans offers a deep dive into the theory and clinical practice of TFP as a treatment for Borderline Personality Disorder. Listen now
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
